Rather than targeting GLP-1 specifically, DS-01 delivers 24 clinically studied strains across multiple categories: gastrointestinal health, gut barrier integrity, gut immune function, dermatological health, cardiovascular health, and micronutrient synthesis
Most cases didn't cause patients to stop treatment
The review itself requires 6 to 12 months, but this clock doesnt begin until the company submits all necessary information
Results: Incidence rates for pancreatitis (adjusted HR [aHR] 9.1, 95% confidence interval [CI] 1.25-66), bowel obstruction (aHR 4.2, 95% CI 1.02-17.4), and gastroparesis (aHR 3.7, 95% CI 1.2-11.9) were significantly higher among users of GLP-1 receptor agonists compared to buproprion-naltrexone users
New Engl
[10] [4] Kidney-related symptoms such as markedly reduced urine output, dark scant urine, or swelling in the legs may indicate acute kidney injury from dehydration and require urgent evaluation